GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (STU:UNC) » Definitions » FFO per Share

UCB (STU:UNC) FFO per Share


View and export this data going back to . Start your Free Trial

What is UCB FFO per Share?

FFO per Share only applies to REITs.


UCB (STU:UNC) Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).